Mehak Pahwa1, Ahmad Sleem2, Omar H Elsayed2, Megan Elizabeth Good2, Rif S El-Mallakh3. 1. Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA. mehak.pahwa@louisville.edu. 2. Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA. 3. Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA. rifaat.elmallakh@louisville.edu.
Abstract
PURPOSE OF REVIEW: Over the last ten years, the treatment of psychosis has seen a near explosion of creative development in both novel agents and new delivery modalities. The current review summarizes these developments over the past decade (2011-2020). We performed a systematic review utilizing PubMed and PsychInfo with the aim of identifying all the RCT and related analyses in adults with psychosis (schizophrenia and mania). RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapine, and inhaled loxapine; and the introduction of new approaches such as olanzapine/samidorphan for olanzapine-associated weight gain, examination of the TAAR1 agonist SEP 363,856 as a test of concept, and the combination of Xanomeline/Trospium, an M1 and M4 muscarinic receptor agonist in conjunction with a peripheral anticholinergic. Last decade has seen a tremendous development in second-generation antipsychotics which provides unprecedented treatment options for clinicians in treating psychosis.
PURPOSE OF REVIEW: Over the last ten years, the treatment of psychosis has seen a near explosion of creative development in both novel agents and new delivery modalities. The current review summarizes these developments over the past decade (2011-2020). We performed a systematic review utilizing PubMed and PsychInfo with the aim of identifying all the RCT and related analyses in adults with psychosis (schizophrenia and mania). RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapine, and inhaled loxapine; and the introduction of new approaches such as olanzapine/samidorphan for olanzapine-associated weight gain, examination of the TAAR1 agonist SEP 363,856 as a test of concept, and the combination of Xanomeline/Trospium, an M1 and M4 muscarinic receptor agonist in conjunction with a peripheral anticholinergic. Last decade has seen a tremendous development in second-generation antipsychotics which provides unprecedented treatment options for clinicians in treating psychosis.
Authors: Eva Agai-Csongor; György Domány; Katalin Nógrádi; János Galambos; István Vágó; György Miklós Keserű; István Greiner; István Laszlovszky; Anikó Gere; Eva Schmidt; Béla Kiss; Mónika Vastag; Károly Tihanyi; Katalin Sághy; Judit Laszy; István Gyertyán; Mária Zájer-Balázs; Larisza Gémesi; Margit Kapás; Zsolt Szombathelyi Journal: Bioorg Med Chem Lett Date: 2012-04-04 Impact factor: 2.823
Authors: Suresh Durgam; Andrew J Cutler; Kaifeng Lu; Raffaele Migliore; Adam Ruth; István Laszlovszky; György Németh; Herbert Y Meltzer Journal: J Clin Psychiatry Date: 2015-12 Impact factor: 4.384
Authors: Miklós Tóth; Andrea Varrone; Carsten Steiger; István Laszlovszky; Attila Horváth; Béla Kiss; István Gyertyán; Nika Adham; Christer Halldin; Balázs Gulyás Journal: Synapse Date: 2013-02-08 Impact factor: 2.562
Authors: Nicholas Seneca; Sjoerd J Finnema; István Laszlovszky; Béla Kiss; Attila Horváth; Gabriella Pásztor; Margó Kapás; István Gyertyán; Sándor Farkas; Robert B Innis; Christer Halldin; Balázs Gulyás Journal: Psychopharmacology (Berl) Date: 2011-05-28 Impact factor: 4.530
Authors: Béla Kiss; Attila Horváth; Zsolt Némethy; Eva Schmidt; István Laszlovszky; Gyula Bugovics; Károly Fazekas; Katalin Hornok; Szabolcs Orosz; István Gyertyán; Eva Agai-Csongor; György Domány; Károly Tihanyi; Nika Adham; Zsolt Szombathelyi Journal: J Pharmacol Exp Ther Date: 2010-01-21 Impact factor: 4.030
Authors: Suresh Durgam; Robert E Litman; Kelly Papadakis; Dayong Li; György Németh; István Laszlovszky Journal: Int Clin Psychopharmacol Date: 2016-03 Impact factor: 1.659
Authors: Martin Schulze Westhoff; Adrian Groh; Sebastian Schröder; Phileas Johannes Proskynitopoulos; Kirsten Jahn; Martin Klietz; Benjamin Krichevsky; Dirk O Stichtenoth; Felix Wedegärtner; Stefan Bleich; Helge Frieling; Johannes Heck Journal: J Neural Transm (Vienna) Date: 2022-09-02 Impact factor: 3.850